The overall response rate (RR) and disease control rate (DCR) of NSCLC patients with uncommon EGFR mutations who received first EGFR‐TKI therapy was 59.1% and 81.8%, respectively (Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.